Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
| Autor: | Kun Zhang, Zhigang Cai, Zhenjie Hu, Yuhong Chen, Guijun Zhu, Zhongheng Zhang, Xixin Yan, Haijun Zhi, Lixia Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty China Circulatory collapse Critical Care medicine.medical_treatment Critical Illness Pneumonia Viral Lung injury Disease cluster 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine Humans 030212 general & internal medicine Pandemics Depression (differential diagnoses) Aged Retrospective Studies Advanced and Specialized Nursing Mechanical ventilation business.industry COVID-19 Retrospective cohort study Middle Aged medicine.disease Intensive Care Units Anesthesiology and Pain Medicine 030228 respiratory system Methylprednisolone Female business Coronavirus Infections medicine.drug |
| Zdroj: | Annals of palliative medicine. 9(4) |
| ISSN: | 2224-5839 |
| Popis: | Background In December, 2019, a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. We aimed to clarify the epidemiology, laboratory examinations, imaging findings, and treatment of critically ill patients with COVID-19 in Hebei province, China. Methods In this retrospective study, the demographic, laboratory and imaging, and treatment data of patients with severe COVID-19 treated in 13 designated hospitals in Hebei were collected and analyzed. Results A total of 319 severe COVID-19 patients were treated at the 13 designated hospitals between 22 January, 2020 and 25 March, 2020. Eventually, 51 critically ill (31 severe cases and 20 critically severe cases) patients were included in the analysis. The patients had an average age of 58.9±13.7 years, and 27 (52.9%) were men. Twenty-one (41.2%) were familial cluster, and 33 (64.7%) had chronic illnesses. The patients in critically severe group had longer duration from symptom to confirmation, more severe infections, more severe lung injury, and a lower percentage of lymphocytes. All 51 patients received antiviral drugs, 47 (92.2%) received antibacterial agents, 49 (96.1%) received traditional Chinese drugs, and 46 (90.2%) received methylprednisolone. The critically severe patients received more fluid and more diuretic treatment; 14 (70.0%) required invasive mechanical ventilation, and 13 (65.0%) developed extrapulmonary complications. Conclusions COVID-19 patients who had underlying diseases and longer confirmation times were more likely to progress to critically severe COVID-19. These patients also presented with a higher risk of respiratory depression, circulatory collapse, extrapulmonary complications, and infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|